Ceribell, the developer of the first AI-powered point-of-care EEG diagnostic system aimed to revolutionize seizure management in acute care, goes public on Nasdaq under the ticker CBLL. Ceribell System, is a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated AI-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Camford Capital has been a proud supporter of the company since 2015. More about the company's announcement is here.
Ceribell team in front of Nasdaq during the company's listing date on the exchange